Lessons learned from SARS epidemics in China may help healthcare professionals prepare for new epidemics, such as human avian flu, say experts in this weeks British Medical Journal.
Mainland China experienced three outbreaks of SARS between November 2002 and May 2004. The first outbreak resulted in a pandemic and caused huge financial loss and social panic, but rigorous control policies prevented further pandemics. Such efforts mean that SARS is currently under control. But what have we learned and how can this help us tackle new epidemics in the future?
Lessons learned include being honest with the public about what is happening, ensuring close collaboration between laboratory workers and health professionals, involving health professionals in developing official policies, and adhering to strict scientific regulations.
So how can we do better next time? SARS has not been eradicated, and humans remain vulnerable to emerging infectious diseases like bird flu, say the authors. As we face up to the threat of future pandemics, we can take encouragement from the fact that many of the uncertainties that arose during the SARS outbreak were resolved over time.
Future strategies should focus on close collaboration between health professionals to contain emergent infections and constant consultation to develop appropriate official policies. An international monitoring network for the early alerting of infectious diseases is also needed. Lessons taught by SARS have given us a new outlook on a devastating human health crisis, and have important implications worldwide, the authors of an article in the British Medical Journal write. What has happened with the spread of the SARS virus must not be allowed to happen again with H5N1. Incessant efforts are needed to improve our preparedness, they conclude.
Reference: What we have learnt from SARS epidemics in China? British Medical Journal. Vol. 333, pp 389-91.
Source: British Medical Journal
COVID-19 Harmonization: Balancing Risks and Benefits of CDC's Latest Move
March 11th 2024The CDC's recent decision to align recommendations for respiratory viruses, particularly COVID-19, has garnered support from the public and infectious disease societies. However, as the Infectious Diseases Society of America (IDSA) lends its backing to the CDC's harmonization efforts, concerns persist regarding the implications of this shift, especially considering the Omicron variant's unique characteristics and the ongoing challenges posed by COVID-19's multi-system impacts.
Voices of Resilience: Q&A With the Editor of "Corona City: Voices From an Epicenter"
March 1st 2024Step into the diverse and poignant world of "Corona City: Voices From an Epicenter" with editor Lorraine Ash, MA. In this insightful Q&A, learn about the origins of this remarkable anthology, the challenges faced in capturing raw, unfiltered narratives of the COVID-19 pandemic, and the lasting impact of these stories on readers and communities alike.
Rare Disease Day 2024: Spotlight on Rare Infectious Diseases
February 29th 2024Rare Disease Day on February 29, 2024, shines a global light on the impact of rare diseases, including rare infectious diseases. With a focus on early diagnosis and treatment access, this day highlights the struggles of those with rare conditions.
COVID-19 Realities: Beyond a Respiratory Virus, Addressing Optimism in Pandemic Management
February 28th 2024A recent commentary by Dr. Amesh Adalja in MedPage Today challenges the perception of COVID-19 as solely a respiratory virus, highlighting its broader impact on the body. This analysis questions the notion that COVID-19 should be managed like common respiratory infections, urging a closer look at vaccine effectiveness, the rise of long COVID, and the need for enhanced measures to curb the virus's spread. Let's explore the complexities of COVID-19 management and the pressing realities faced by the US and the world.